Vimarsana
Biggest News Aggregation in the World

Page 6 - Risk Evaluation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Risk Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Risk Evaluation Today - Breaking & Trending Today

Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma -April 05, 2024 at 11:31 pm EDT - Vimarsana News

Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma -April 05, 2024 at 11:31 pm EDT

Published: April 6, 2024

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse ...

Source: marketscreener.com
Related Topics:
United StatesNew JerseyHemophagocytic LymphohistiocytosisSurbhi SidanaBirk VanderweeYing HuangMedicinal Devices AgencyEuropean CommissionOncologic Drugs Advisory CommitteeLegend Biotech CorporationDrug AdministrationJapan Ministry Of HealthJanssen Biotech IncExchange Commission OnAmerican Cancer SocietyLegend BiotechB Cell Maturation AntigenChief Executive OfficerDrugs Advisory CommitteeAssistant ProfessorMarrow TransplantationCellular TherapyStanford University SchoolSenior Vice PresidentGlobal Manufacturing
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy -April 05, 2024 at 09:08 am EDT - Vimarsana News

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy -April 05, 2024 at 09:08 am EDT

Published: April 5, 2024

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety...

Source: marketscreener.com
Related Topics:
United KingdomGreat BritainBryan CampbellBristol Myers SquibbAl Olaa AbdallahHemophagocytic LymphohistiocytosisEuropean UnionUniversity Of KansasUs Myeloma Innovations Research CollaborativeExchange CommissionDrug AdministrationImportant Safety InformationCytokine Release SyndromeNeurologic ToxicitiesMacrophage Activation SyndromeProlonged CytopeniaSecondary HematologicalCell TherapyBristol MyersChip BairdClinical Associate ProfessorClinical DirectorHematologic MalignanciesCellular TherapeuticsInnovations Research
FDA OKs Danicopan for Extravascular Hemolysis in PNH - Vimarsana News

FDA OKs Danicopan for Extravascular Hemolysis in PNH

Published: April 2, 2024

A tablet has been approved for a common complication during treatment for a rare blood disorder.

Source: medscape.com
Related Topics:
Drug AdministrationRisk EvaluationMitigation StrategyPatient SafetyBlood TransfusionBlood ClotBiliary DiseaseAllbladder DiseaseParoxysmal Nocturnal HemoglobinuriaNh Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal HaemoglobinuriaParoxysmal Nocturnal Hemoglobinuria Pnh Covid 19019 Novel Coronavirus019 NcovUhan CoronavirusUman Coronavirus Hku1Uman Coronavirus Oc43
Pyros Pharmaceuticals Announces VIGPODER™ (vigabatrin) is Now Available - Vimarsana News

Pyros Pharmaceuticals Announces VIGPODER™ (vigabatrin) is Now Available

Published: April 1, 2024

PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr 1, 2024--

Source: eagletribune.com
Related Topics:
United StatesEdwin UrrutiaMichael SmithChild Neurology SocietyEpilepsy ResearchAmerican Academy Of NeurologyPyros PharmaceuticalsPyros Pharmaceuticals IncPrescribing InformationtoImportant SafetyBusiness WirePyros Total CareChief Executive OfficerTotal CareAmerican AcademyRisk EvaluationMitigation StrategyPrescribing InformationVigabatrin Risk EvaluationMagnetic Resonance ImagingIntramyelinic EdemaChild NeurologyWest DelphiInvestigational Drugs
Are Federal Agencies Coming for Ketamine Clinics? - Vimarsana News

Are Federal Agencies Coming for Ketamine Clinics?

Published: April 1, 2024

Compliance plans can help in the face of possible regulatory scrutiny

Source: medpagetoday.com
Related Topics:
Drug Enforcement AgencyDepartment Of JusticeRisk EvaluationMitigation StrategyMedicare AdvantageChronic PainKetamine Product